NICM
MYGN icon

Neo Ivy Capital Management’s Myriad Genetics MYGN Stock Holding History

Neo Ivy Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,488
Closed -$85K – 356
2024
Q2 		$85K Buy
+3,488
New +$76.5K 0.02% 208

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Neo Ivy Capital Management's MYGN Position: Q3 2024 in Review

Neo Ivy Capital Management sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 3,488 shares — an estimated $85K sold.

Neo Ivy Capital Management first reported a position in MYGN in Q2 2024 and held it in 1 quarter. The position peaked at $85K in Q2 2024. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

  • Neo Ivy Capital Management reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
  • Neo Ivy Capital Management sold 3,488 Myriad Genetics shares in Q3 2024, an estimated $85K.
  • Neo Ivy Capital Management first reported a position in Myriad Genetics in Q2 2024 and held it in 1 quarter.
  • Neo Ivy Capital Management's Myriad Genetics position peaked at $85K in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Neo Ivy Capital Management's 13F filing for Q3 2024, filed 18 Nov 2024.